Application of fludarabine phosphate (Fludara®) in the treatment of patients with lymphoproliferative diseases

E. Hadjiev, K. Alexandrova, M. Ziumbiuleva, G. Yotov, R. Ousheva

Résultats de recherche: Contribution à un journalArticleRevue par des pairs

Résumé

Actually the incidence of lymphoproliferative diseases has increased steadily over the past 20 years. With the standard treatment options there has been no demonstrable improvement in overall survival. As a consequence, the therapy of indolent non-Hodgkin's lymphoma (NHL) remains controversial. In the last years the treatment of patients with NHL has changed because of the introduction of new agents, mainly the purine analogues. We report our experience with fludarabine phosphate in 7 patients with chronic lymphocytic leukaemia and 2 with indolent NHL. The mean number of cycles received was 5.5 (range 1-10). The overall response rate was 77%, with 3 complete remissions and 4 partial responses. The treatment was well tolerated. The most common adverse effect was myelosupression. The major complications were infections in 2 patients. Fludarabine phosphate appears to be an effective therapy for patients with lymphoproliferative diseases with a reasonable safety profile. The future of fludarabine appears to be in combination with other chemotherapeutics, monoclonal antibodies or other experimental agents.

langue originaleAnglais
Pages (de - à)78-80
Nombre de pages3
journalClinical and Transfusion Haematology
Volume42
Numéro de publication1-2
étatPublié - 1 déc. 2006
Modification externeOui

Contient cette citation